IVIG Privigen denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Privigen as Duplicate Therapy — and Why You Can Appeal

Privigen (immune globulin intravenous, 10%) is one of several IVIG formulations on the market. A duplicate-therapy denial from UnitedHealthcare (UHC) typically means the plan believes you are already receiving — or have recently received — another IVIG product or an immune globulin therapy that serves the same clinical purpose. These denials often arise from billing overlap, a recent switch between IVIG brands, or the plan's assumption that subcutaneous immunoglobulin (SCIG) and IVIG are interchangeable for every patient.

## Why This Denial Is Appealable

Duplicate-therapy denials are frequently administrative errors. If you are transitioning from one IVIG brand to Privigen, or if your prescriber has determined that Privigen specifically is appropriate for you (e.g., tolerability profile, infusion facility formulary), that clinical rationale distinguishes the new authorization from a true duplicate. UHC must conduct a full-and-fair review of your individual circumstances and cannot deny solely on a formulary-overlap assumption.

## Federal Appeal Framework

• ERISA §503 (employer plans): Requires UHC to disclose the specific clinical criteria used and to evaluate your appeal on its individual merits.
• ACA §2719 / State external review: After internal levels are exhausted, an independent reviewer examines whether the duplicate-therapy determination was correct. Act within approximately four months of your denial notice.
• Expedited review: Request it if your next infusion is imminent or if a gap in therapy poses clinical risk.

## Your Appeal Process

1. Obtain the denial letter and UHC's Privigen/IVIG coverage policy. 2. Identify exactly which therapy UHC claims is duplicative and confirm whether it is currently active. 3. File a Level 1 internal appeal clarifying the clinical distinction and current medication list. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Current medication list: A complete, dated list from your prescriber confirming which therapies are active and which have been discontinued.
• Discontinuation records: If a prior IVIG product was stopped before Privigen was ordered, include the stop date and reason.
• Clinical rationale for Privigen specifically: Your prescriber's explanation of why Privigen (rather than a substitute) is appropriate — e.g., formulation, excipient tolerance, infusion-site availability.
• Diagnosis and indication confirmation: Specialist notes tying the Privigen order to your specific FDA-recognized indication.
• Medical-necessity letter: Explicitly addressing why this is not a duplicate and why continuation or initiation of Privigen is medically necessary.

## Criteria-Mapping Strategy

Request UHC's published clinical policy for IVIG and duplicate-therapy definitions. Identify each criterion used to classify a therapy as duplicative, then rebut each point with specific chart evidence. The most effective appeals demonstrate clearly — in a side-by-side table — that no overlapping active authorization exists, or that the products serve clinically distinct roles for your situation.